About Sermorelin
Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.
Sermorelin acetate is a synthetic 29-amino-acid peptide (GHRH(1-29)NH2) corresponding to the biologically active N-terminal fragment of endogenous growth hormone-releasing hormone, developed as a prescription pharmaceutical to stimulate endogenous GH secretion from the pituitary gland as a diagnostic and therapeutic agent for GH deficiency. Sermorelin acts on pituitary somatotrophs via GHRH receptors to stimulate pulsatile GH release, preserving the natural feedback regulation of the GH axis — an advantage over direct exogenous GH administration — and multiple randomized controlled trials have established its pharmacokinetic and pharmacodynamic profile in populations with GH insufficiency including post-irradiation hypopituitarism. The compound received FDA approval as Geref (Serono) for diagnosis and treatment of GH deficiency in children; approval was voluntarily withdrawn by the manufacturer in 2008 for commercial rather than safety reasons, leaving the underlying human evidence base intact, and compounded sermorelin has since been widely used off-label in adult anti-aging and hormone optimization practice. Sermorelin is currently available only through compounding pharmacies under prescriber supervision; it is not FDA-approved for any current indication, and its use in adults represents off-label prescribing outside the regulatory framework established by its original pediatric approval. Sermorelin is available through telehealth platforms and hormone optimization clinics across the United States and is dispensed by compounding pharmacies under licensed prescriber supervision. Patients searching for sermorelin providers near them or via telehealth can use the PeptideBase directory to browse verified clinics and telehealth platforms offering sermorelin by location. Sermorelin bodybuilding and anti-aging research contexts have driven its widespread compounded use in adults, though these applications are off-label and outside the original pediatric approval framework. Sermorelin near me: sermorelin is available through licensed anti-aging clinics, hormone health practices, and telehealth platforms that specialize in growth hormone axis support. Because sermorelin requires a prescription, access involves a clinical consultation — many providers now offer this remotely via telehealth, eliminating the need for in-person visits. For those searching for sermorelin providers near them, PeptideBase maintains a directory of verified clinics and telehealth platforms offering sermorelin protocols across the United States. Sermorelin and ipamorelin together: yes, sermorelin and ipamorelin are frequently combined in clinical research and compounded hormone optimization protocols. The two peptides act on different receptors — sermorelin on GHRH receptors (stimulating the GHRH pathway) and ipamorelin on ghrelin receptors (GHS-R1a) — and their mechanisms are complementary rather than redundant. Combining a GHRH analog like sermorelin with a GHRP like ipamorelin produces synergistic GH release, consistent with the well-established pharmacological principle that GHRH and GH secretagogues act additively at the pituitary. Ipamorelin is specifically valued in this combination for its selectivity — it stimulates GH without the cortisol or prolactin co-stimulation that characterizes less selective GHRPs such as GHRP-2 or GHRP-6. The sermorelin + ipamorelin combination (and its extension, the sermorelin + CJC-1295 + ipamorelin triple protocol) is among the most commonly prescribed compounded GH secretagogue regimens in anti-aging and hormone optimization practice. Providers offering combination GH secretagogue protocols are listed in the PeptideBase directory.
Sermorelin Benefits & Research Areas
Research Signals
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- Not Evaluated
- Source
- View FDA source →
Previously FDA-approved for pediatric GH deficiency; approval withdrawn 2008. Now used off-label via compounding pharmacies.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
2 sources cited · 2 moderate
2 RCTs
The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency
European Journal of Endocrinology · 2000
Research in a randomized controlled dose-response study found that GHRH(1-29)NH2 (sermorelin) produced a dose-dependent GH secretory response in healthy controls that was markedly attenuated in adults with post-irradiation GH insufficiency, demonstrating the pituitary somatotroph responsiveness to GHRH as the mechanism underlying sermorelin-based GH stimulation.
The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin in growth hormone pulse generation
Clinical Endocrinology · 1999
Research in a randomized peptide clamp study demonstrated that continuous GHRH(1-29) infusion significantly amplified GH secretory peak concentrations in healthy adults, and that the combination of continuous GHRH with intermittent somatostatin withdrawal reliably generated pulsatile GH release, clarifying the mechanistic basis for GHRH analog-based GH augmentation.
Sermorelin Side Effects & Safety Considerations
Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.
Reported contraindications & considerations
Common monitoring markers in research protocols
Sermorelin clinical protocols measure IGF-1 as the primary marker of GH axis response. Fasting glucose and insulin are standard baseline assessments given GH's effect on insulin sensitivity.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Known Interactions
1 notedResearch suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.
Prakash A & Goa KL (1999) Sermorelin: A Review of its Use. BioDrugs; Raun K et al. (1998) Ipamorelin. Eur J Endocrinol
These interactions reflect published research and are provided for educational purposes only. This is not medical advice. Consult a qualified healthcare professional before combining any compounds or medications.
Research Stacks
Browse all →Where to Buy Sermorelin — Providers & Availability
414 providersCoverage expanding
No verified providers currently list Sermorelin. Get notified when one does, or explore providers carrying similar peptides in the Performance category.
Stay updated on verified Sermorelin providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Sermorelin
Sermorelin acetate is a synthetic 29-amino-acid peptide (GHRH(1-29)NH2) corresponding to the biologically active N-terminal fragment of endogenous growth hormone-releasing hormone, developed as a prescription pharmaceutical to stimulate endogenous GH secretion from the pituitary gland as a diagnostic and therapeutic agent for GH deficiency. Sermorelin acts on pituitary somatotrophs via GHRH receptors to stimulate pulsatile GH release, preserving the natural feedback regulation of the GH axis — an advantage over direct exogenous GH administration — and multiple randomized controlled trials have established its pharmacokinetic and pharmacodynamic profile in populations with GH insufficiency including post-irradiation hypopituitarism.
pulsatile GH release via direct GHRH receptor agonism at the pituitary, endogenous GH axis restoration — preserves natural pulse patterns unlike exogenous GH, lean mass, sleep quality, and metabolic improvements in anti-aging clinical research, subcutaneous injection — widely available through telehealth anti-aging providers.
Research on Sermorelin primarily documents effects related to pulsatile GH release via direct GHRH receptor agonism at the pituitary and endogenous GH axis restoration — preserves natural pulse patterns unlike exogenous GH and lean mass, sleep quality, and metabolic improvements in anti-aging clinical research and subcutaneous injection — widely available through telehealth anti-aging providers. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Sermorelin include active cancer history, pregnant or nursing. This is educational information only — consult a qualified healthcare professional before use.
414 providers in the directory currently offer Sermorelin.
Research in a randomized controlled dose-response study found that GHRH(1-29)NH2 (sermorelin) produced a dose-dependent GH secretory response in healthy controls that was markedly attenuated in adults with post-irradiation GH insufficiency, demonstrating the pituitary somatotroph responsiveness to GHRH as the mechanism underlying sermorelin-based GH stimulation.
Sermorelin is featured in the following research stacks on PeptideBase: Sermorelin + GHRP-2: GH Stimulation & Recovery.